Ireland-based WhiteSwell, the company advancing the treatment of acute decompensated heart failure, has raised a $30 million Series B funding round.

The round was led by RA Capital Management and an InCube Ventures syndicate, with participation from other backers.

WhiteSwell plans use the funds from the round to support product advancement.

With the funding, the company also plans to back a pivotal study of its innovative technology for the treatment of acute decompensated heart failure.